MYC and MCL1 mRNA downregulation has been described previously from the blood of patients treated with enitociclib during dose escalation and across many cancer indications including NHL and solid tumors using a qPCR clinical trial assay (28, 29). This evidence concerns the gene MYC and non-Hodgkin lymphoma.